Invesco
AVXL icon

Invesco’s Anavex Life Sciences AVXL Stock Holding History

Invesco’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
109,948
+37,518
+52% +$111K ﹤0.01% 3460
2026
Q1 		$222K Buy
72,430
+26,943
+59% +$117K ﹤0.01% 3451
2025
Q4 		$162K Sell
45,487
-11,212
-20% -$68.7K ﹤0.01% 3577
2025
Q3 		$505K Sell
56,699
-807,260
-93% -$8.19M ﹤0.01% 3223
2025
Q2 		$7.97M Buy
863,959
+309,605
+56% +$2.64M ﹤0.01% 1929
2025
Q1 		$4.76M Sell
554,354
-60,694
-10% -$573K ﹤0.01% 2183
2024
Q4 		$6.61M Buy
615,048
+590,639
+2,420% +$4.54M ﹤0.01% 2104
2024
Q3 		$139K Sell
24,409
-875
-3% -$5.05K ﹤0.01% 3574
2024
Q2 		$107K Sell
25,284
-2,956
-10% -$12K ﹤0.01% 3743
2024
Q1 		$144K Buy
28,240
+306
+1% +$1.72K ﹤0.01% 3702
2023
Q4 		$260K Sell
27,934
-23,323
-46% -$161K ﹤0.01% 3478
2023
Q3 		$336K Buy
51,257
+19,603
+62% +$156K ﹤0.01% 3397
2023
Q2 		$257K Sell
31,654
-239
-0.7% -$2.05K ﹤0.01% 3546
2023
Q1 		$273K Buy
31,893
+1,601
+5% +$16K ﹤0.01% 3530
2022
Q4 		$281K Sell
30,292
-2,899
-9% -$31K ﹤0.01% 3536
2022
Q3 		$342K Buy
33,191
+3,514
+12% +$37.1K ﹤0.01% 3454
2022
Q2 		$297K Sell
29,677
-671
-2% -$6.36K ﹤0.01% 3587
2022
Q1 		$374K Sell
30,348
-404,891
-93% -$4.98M ﹤0.01% 3538
2021
Q4 		$7.55M Buy
435,239
+398,718
+1,092% +$7.58M ﹤0.01% 2176
2021
Q3 		$655K Sell
36,521
-561,977
-94% -$11.2M ﹤0.01% 3304
2021
Q2 		$13.7M Sell
598,498
-526,867
-47% -$7.8M ﹤0.01% 1859
2021
Q1 		$16.8M Buy
1,125,365
+900,652
+401% +$9.84M ﹤0.01% 1657
2020
Q4 		$1.21M Buy
+224,713
New +$1.18M ﹤0.01% 2863
2020
Q3 		– Sell
-133,005
Closed -$654K – 3624
2020
Q2 		$654K Buy
+133,005
New +$503K ﹤0.01% 3009

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco's AVXL Position: Q2 2026 in Review

Invesco increased its Anavex Life Sciences (AVXL) stake by 52% in Q2 2026, buying an estimated $111K and bringing the position to 109,948 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #3460.

Invesco first reported a position in AVXL in Q2 2020 and has held it in 24 quarters since. The position peaked at $16.8M in Q1 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Invesco held 109,948 shares of Anavex Life Sciences worth $285K as of Q2 2026.
  • Invesco bought 37,518 Anavex Life Sciences shares in Q2 2026, an estimated $111K.
  • Anavex Life Sciences made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3460 holding.
  • Invesco first reported a position in Anavex Life Sciences in Q2 2020 and has held it in 24 quarters since.
  • Invesco's Anavex Life Sciences position peaked at $16.8M in Q1 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.